RxDoctor Payments Data

Hong Nguyen, MD

Internal Medicine · Marrero, LANPI 1982615142

Payments from drug & device makers

$14,718in general payments, 2019–2025

Across 832 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$818
  • Boehringer Ingelheim$757
  • plus $7K from 37 others

What the payments were for

  • Food & beverage$14,658100%
  • Education$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,718 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$58,359
Medicare patients
113
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$169,222
JardianceEmpagliflozin164$144,882
MounjaroTirzepatide63$66,482
FarxigaDapagliflozin Propanediol81$63,347
EliquisApixaban60$49,224
JanuviaSitagliptin Phosphate53$44,835
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$44,677
TrulicityDulaglutide27$42,065
LinzessLinaclotide32$26,993
XareltoRivaroxaban35$26,519
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$24,168
Soliqua 100-33Insulin Glargine/Lixisenatide14$19,698
Synjardy XrEmpagliflozin/Metformin Hcl27$16,401
Tresiba Flextouch U-100Insulin Degludec32$14,895
GlyxambiEmpagliflozin/Linagliptin22$12,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$757$174,200213 claims
Novo NordiskOzempic$664$169,222154 claims
Lilly USA, LLCMounjaro, Trulicity$1,127$108,54890 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,528$87,516112 claims
PfizerEliquis$67$49,22460 claims
MerckJanuvia$126$44,83553 claims
GSKTrelegy Ellipta$1,318$44,67756 claims
AbbVieLinzess, Synthroid$2,167$28,65846 claims
Johnson & JohnsonXarelto$818$26,51935 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$269$19,69814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →